Werewolf Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Werewolf Therapeutics (Nasdaq: HOWL) will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The pre-recorded presentation will be available on-demand starting 7:00 AM EDT on September 12. Werewolf is focused on conditionally activated therapeutics that stimulate the immune system targeting cancer. Their leading candidates, WTX-124 and WTX-330, aim to improve treatment for solid tumors by activating selectively within the tumor microenvironment while remaining inactive elsewhere.

WATERTOWN, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present virtually at the H.C. Wainwright 24^th Annual Global Investment Conference, taking place in New York, NY from September 12-14, 2022.

Management’s pre-recorded presentation will be made available on-demand at 7:00 AM EDT on September 12. A link to the webcast will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay of the webcast will be available for approximately 90 days.

About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance both WTX-124 and WTX-330 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. To learn more visit www.werewolftx.com.

Investor Contact:
Josh Rappaport
Stern IR
212.362.1200
Josh.Rappaport@sternir.com

Media Contact:
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com 

Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com 

FAQ

What is the date of Werewolf Therapeutics' presentation at the H.C. Wainwright Conference?

Werewolf Therapeutics will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12 to 14, 2022.

Where can I watch the Werewolf Therapeutics presentation?

The pre-recorded presentation by Werewolf Therapeutics will be available on-demand at 7:00 AM EDT on September 12, 2022, via their investor events page.

What are the main focuses of Werewolf Therapeutics?

Werewolf Therapeutics specializes in developing conditionally activated therapeutics that stimulate the immune system for cancer treatment.

What are the key product candidates of Werewolf Therapeutics?

Werewolf Therapeutics' main product candidates are WTX-124 and WTX-330, designed for treating solid tumors through selective activation in the tumor microenvironment.

What platform does Werewolf Therapeutics use for their drug development?

Werewolf Therapeutics leverages their proprietary PREDATOR™ platform to develop their therapeutics.